Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection

Transplantation

Volumn 93, Issue 1, 2012, Pages 24-31

  Kakuta, Yoichi ^a   Okumi, Masayoshi ^a   Miyagawa, Shuji ^a   Tsutahara, Koichi ^a   Abe, Toyofumi ^a   Yazawa, Koji ^a   Matsunami, Katsuyoshi ^b   Otsuka, Hideaki ^b   Takahara, Shiro ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

CCR5; Chemokine; CXCR3; Kidney transplantation; Macrophage

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 18; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PERFORIN;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; GENE EXPRESSION; GRAFT SURVIVAL; IMMUNOCHEMISTRY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EPITHELIUM; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; UPREGULATION;

AMIDES; ANIMALS; CELL MOVEMENT; CHEMOKINES; CYCLOSPORINE; CYTOKINES; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MACROPHAGES; MALE; MODELS, ANIMAL; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; RECEPTORS, CCR5; RECEPTORS, CXCR3; TRANSPLANTATION, HOMOLOGOUS;

EID: 84655160799     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823aa585     Document Type: Article

References (35)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. McDonald S, Russ G, Campbell S, et al. Kidney transplant rejection in Australia and New Zealand: Relationships between rejection and graft outcome. Am J Transplant 2007; 7: 1201.
3. Barry M, Bleackley RC. Cytotoxic T lymphocytes: All roads lead to death. Nat Rev Immunol 2002; 2: 401.
4. Hancock WW, Thomson NM, Atkins RC. Composition of interstitial cellular infiltrate identified by monoclonal antibodies in renal biopsies of rejecting human renal allografts. Transplantation 1983; 35: 458.
5. Jose MD, Ikezumi Y, van Rooijen N, et al. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Transplantation 2003; 76: 1015.
6. Qi F, Adair A, Ferenbach D, et al. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation. Transplantation 2008; 86: 1267.
7. Hancock WW, Wang L, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15: 479.
8. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108.
9. Mackay CR. Chemokines: Immunology's high impact factors. Nat Immunol 2001; 2: 95.
10. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
11. Luster AD. Chemokines-Chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436.
12. Horiguchi K, Kitagawa-Sakakida S, Sawa Y, et al. Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 2002; 21: 1090.
13. Morita K, Miura M, Paolone DR, et al. Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 2001; 167: 2979.
14. Zhao DX, Hu Y, Miller GG, et al. Differential expression of the IFNgamma- inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002; 169: 1556.
15. Russell ME, Adams DH, Wyner LR, et al. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 1993; 90: 6086.
16. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35.
17. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515.
18. Dehmel S, Wang S, Schmidt C, et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves longterm renal allograft outcome. Eur J Immunol 2010; 40: 267.
19. Luckow B, Joergensen J, Chilla S, et al. Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. Eur J Immunol 2004; 34: 2568.
20. Schröppel B, Zhang N, Chen P, et al. Differential expression of chemokines and chemokine receptors in murine islet allografts: The role of CCR2 and CCR5 signaling pathways. J Am Soc Nephrol 2004; 15: 1853.
21. Schröder C, Pierson RN, Nguyen BN, et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 2007; 179: 2289.
22. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758.
23. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199.
24. Jun L, Kailun Z, Aini X, et al. Combined treatment with chemokine receptor 5 blocker and cyclosporine induces prolonged graft survival in a mouse model of cardiac transplantation. J Heart Lung Transplant 2010; 29: 461.
25. Schnickel GT, Bastani S, Hsieh GR, et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008; 180: 4714.
26. Akashi S, Sho M, Kashizuka H, et al. A novel small-molecule compound targeting CCR5 and CXCR3 prevents acute and chronic allograft rejection. Transplantation 2005; 80: 378.
27. Xu H, Firdawes S, Yamamoto A, et al. Effects of blocking the chemokine receptors, CCR5 and CXCR3, With TAK-779 in a rat small intestinal transplantation model. Transplantation 2008; 86: 1810.
28. Takama Y, Miyagawa S, Yamamoto A, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model. Transpl Immunol 2011; 25: 49.
29. McLean AG, Hughes D, Welsh KI, et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63: 374.
30. Raftery MJ, Seron D, Koffman G, et al. The relevance of induced class II HLA antigens and macrophage infiltration in early renal allograft biopsies. Transplantation 1989; 48: 238.
31. Croker BP, Clapp WL, Abu Shamat AR, et al. Macrophages and chronic renal allograft nephropathy. Kidney Int Suppl 1996; 57: S42.
32. Pilmore HL, Painter DM, Bishop GA, et al. Early up-regulation of macrophages and myofibroblasts: A new marker for development of chronic renal allograft rejection. Transplantation 2000; 69: 2658.
33. Le Meur Y, Jose MD, Mu W, et al. Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Transplantation 2002; 73: 1318.
34. Yuan R, El-Asady R, Liu K, et al. Critical role for CD103+CD8+ effectors in promoting tubular injury following allogeneic renal transplantation. J Immunol 2005; 175: 2868.
35. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96: 5698.